Siemens Healthineers Pushes AI Oncology on the World Stage, but a Plodding Diagnostics Unit Drags the Stock Down

Siemens Healthineers unveils AI-powered photon-counting CT for radiotherapy, but diagnostics slide and guidance cut send stock near 52-week low. Analysts slash targets.

On the exhibition floor in Stockholm, Siemens Healthineers is selling the future of cancer care. At the European Society for Radiotherapy and Oncology congress this week, the German medtech group unveiled a photon-counting CT scanner for radiation therapy — the NAEOTOM Alpha Prime RT Pro Edition — designed to distinguish tissue more precisely while lowering radiation exposure. The message is clear: oncology, powered by artificial intelligence, is where the company sees its next growth chapter.

Yet back in Frankfurt, the share price tells a different story. The stock closed at €33.63, barely above its 52-week trough, having shed around 24% since the start of the year.

The disconnect between strategic ambition and market sentiment is stark. While the imaging and Varian cancer-therapy divisions are churning out solid numbers, the diagnostics arm keeps dragging the group into the red.

Diagnostics: structural woes and a 6.5% revenue slide

In the second fiscal quarter, comparable revenue in the diagnostics segment dropped 6.5% to roughly €985m. China’s shift to volume-based procurement and lower reimbursement rates are the main culprits. That hit pushed the division’s adjusted EBIT margin down to just 0.9%.

By contrast, the core imaging business held up well, posting comparable sales growth of 6.1% to nearly €3bn and an adjusted EBIT margin of 22.4%. Varian, the cancer therapy subsidiary, grew 7.5% in comparable terms. Group-wide, reported revenue fell 3.9% to about €5.68bn.

Management responded by trimming the full-year outlook. Comparable revenue growth is now seen at 4.5% to 5%, down from the earlier 5.0% to 6.0% range. Adjusted earnings per share are expected between €2.20 and €2.30, versus a prior ceiling of €2.40. Additional supply-chain costs for more expensive memory chips and logistics are set to shave roughly €0.05 off per-share earnings.

Analysts race to cut targets

The guidance change triggered a flurry of target reductions. Jefferies moved first on Thursday, slashing its price objective from €60 to €50 while keeping a “Buy” rating, citing the diagnostics overhang. Deutsche Bank followed on Friday, lowering its target from €42 to €38 with a “Hold” stance. Analyst Falko Friedrichs argued that even the reduced corporate goals will require a marked upturn in growth and margins.

J.P. Morgan, still on an “Overweight” recommendation, trimmed its target to €55.80 in May. The crossfire of downgrades underscores a market that sees the diagnostics unit as a structural drag that will cap valuation until it is resolved.

Where AI and cancer care aim to shift the narrative

That resolution may be slow in coming, but the ESTRO congress offers a glimpse of what Siemens Healthineers wants to be when it grows up. The company is leaning heavily into the “AI-Rad Companion”, a software suite that automates the segmentation of organs and tumour tissue. For cash-strapped clinics with scarce radiation therapists, faster planning translates directly into better patient throughput — and, Siemens hopes, into a stickier platform relationship.

Varian hosted its own summit at the congress for radio-oncology specialists, reinforcing the strategy of bundling imaging, planning and therapy into an integrated oncology workflow.

Still, the near-term catalyst for the stock may be structural rather than technological. The formal carve-out of the diagnostics business, long speculated, is now a concrete test point. If the separation can lift the earnings drag, the AI-driven oncology story might finally break through to investors. Until then, Siemens Healthineers remains a tale of two halves: one that runs fast, and one that runs in place.

The next quarterly report lands in July 2026. It will show whether the hoped-for recovery in diagnostics is beginning — and whether the spin-off debate is moving from talk to action.